Myeloma and Plasma Cell Dyscrasias Course

Myeloma and Plasma Cell Dyscrasias Course is organized by American Association for Cancer Research (AACR) and will be held from Oct 02 - 05, 2020 at The Westin Copley Place, Boston, Boston, Massachusetts, United States of America.

Accreditation:
AACR has designated this live activity for a maximum of 17.25 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 17.25 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Description:
The research being presented at this conference will address some of the needs mentioned above. The program was designed to discuss advances in basic and translational research (genetics, risk assessment of precursor conditions, monitoring, drug resistance, etc.) and evaluate their application to improve clinical outcomes.

Learning Objectives:
After participating in this CME activity, physicians should be able to:
• Explain the spectrum of precursor conditions and evaluate their risk of progression to myeloma.
• Provide examples of current technologies to diagnose and monitor myeloma and precursor conditions.
• Provide examples of the latest research in myeloma genetics and the study of the myeloma microenvironment.
• Identify current therapeutic options to treat myeloma, including combination therapies and immunotherapeutics.
• Articulate various mechanisms of drug resistance and therapeutic evasion.

Additional details will be posted as soon as information is available.